Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

By afschroeder • May 16, 2026

Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani N, Rueda MJ, Cardoso A, Genovese MC, Armstrong AW, Strober B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol. 2026 May 15:e261753. doi: 10.1001/jamadermatol.2026.1753. Epub ahead of print. PMID: 42139049; PMCID: PMC13179568.

Tags: Dermatology, Publications

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib[...]

Use of ancillary studies in pediatric spitzoid neoplasms: A retrospective cohort study

Chen A, Krenitsky A, Perry SS, Tan KW, Swick BL, Anderson KR, Barry KK, Kelsey B, Carlberg VM, Coughlin CC, Craddock M, Fadzeyeva H, Ferringer[...]

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52[...]